• Roivant won FDA clearance for LISRAYA (brepocitinib) 30 mg to treat adults with dermatomyositis in the U.S.
• Launch starts immediately; product positioned as a once-daily oral TYK2/JAK1 inhibitor, first targeted therapy cleared for the disease.
• Approval based on the Phase 3 VALOR trial; 55% reached moderate-or-better improvement with minimal or no steroid use at week 52.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271529PRIMZONEFULLFEED9817373) on August 27, 2026, and is solely responsible for the information contained therein.